Amagasaki, Japan

Kazuteru Wada

This inventor holds 4 USPTO granted patents. Top assignees: Mitsubishi Tanabe Pharma Corporation, Tanabe Seiyaku Company, Limited. Active years: 2006-2009.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kazuteru Wada. Retrieved from https://idiyas.com/inventor/kazuteru-wada

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2006-2009

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Kazuteru Wada: Innovator in Pharmaceutical Chemistry

Introduction

Kazuteru Wada is a notable inventor based in Amagasaki, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds.

Latest Patents

Wada holds 4 patents, with his latest inventions focusing on condensed polycyclic compounds. These compounds are useful as phosphodiesterase 4 inhibitors, which are important in various therapeutic applications. His innovative work includes a pharmaceutical composition that contains these compounds, demonstrating his commitment to advancing medical science.

Career Highlights

Throughout his career, Kazuteru Wada has worked with prominent companies in the pharmaceutical industry. He has been associated with Mitsubishi Tanabe Pharma Corporation and Tanabe Seiyaku Company, Limited. His work in these organizations has allowed him to contribute to significant advancements in drug development.

Collaborations

Wada has collaborated with esteemed colleagues, including Tatsuzo Ukita and Yoshihiro Terakawa. These partnerships have fostered a collaborative environment that enhances innovation and research in the pharmaceutical sector.

Conclusion

Kazuteru Wada's contributions to pharmaceutical chemistry and his innovative patents highlight his role as a key figure in the industry. His work continues to impact the development of new therapeutic options.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…